Методика трансартериальной химиоэмболизации при первичных и метастатических опухолях печени

Литература:
1. Venook АР, Papandreou С, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 (4): 5-13
2. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surg Clin North Am 2013; (9): 1423-1450
3. Craig JR, Peters RL, Edmondson HA. Tumors of the Liver and Intrahepatic Bile Ducts. Atlas of Tumor Pathology, 2nd series, 26. Washington, DC: Armed Forces Institute of Pathology, 1989
4. Pickren JW, Tsukada Y, Lane WW. Liver metastases: analysis of autopsy data. In: Weiss L, Gilbert HA, eds. Liver Metastasis. Boston, MA: Hall Medical Publishers, 1982; p. 2-18
5. Hong SN, Lee SY, Choi MS, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005; 39: 247-52
6. Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004; 240: 102-7
7. Allemann P, Demartines N, Bouzourene H, et al. Long-term outcome after liver resection for hepatocellular carcinoma larger than 10cm. World J Surg 2013; 37 (2): 452-458
8. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; 11:1057-77
9. Eynde M van den, Hendlisz A. Treatment of colorectal liver metastases: a review. Rev Recent Clin Trials 2009; 4: 56-62
10. Lencioni R, Chen XP, Dagher L, Venook AP Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: How can outcomes be improved? Oncologist 2010; 15 (Suppl 4): 42-52
11. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surgery 2004; 240 (4): 644-58
12. Namasivayam S, Salman K, Mittal PK, et al. Hypervascular hepatic focal lesions: spectrum of imaging features. Curr Probl Diagn Radiol 2007; 36: 107-23
13. Sahani DV, Kalva SP Imaging the liver. Oncologist 2004; 9: 385-97
14. Brink JA. Use of high concentration contrast media (HCCM): principles and rationale — body CT. Eur J Radiol 2003; 45 (Suppl 1):53-8
15. Гранов Д.А., Таразов П.Г. Рентгеноэнодоваскулярные вмешательства в лечении злокачественных опухолей печени. СПб.: Фолиант, 2002
16. Гранов A.M., Давыдов М.И. Интервенционная радиология в онкологии (пути развития и технологии). СПб.: Фолиант, 2007
17. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. The Oncologist 2003; 8: 553-66
18. Ramsey DE, Kernagis LY, Soulen MC, et al. Chemoembolization of hepatocellular carcinoma. J Vase Interv Radiol 2002; 13:211-21
19. Kruskal JB, Hlatky L, Hahnfeldt P, et al. In-vivo and in-vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vase Interv Radiol 1993;4:741-8
20. Huang K, Zhou Q, Wang R, et al. Doxorubicineluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 920-925
21. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25
22. Ono Y, Yoshimasu T, Ashikaga R, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 2000; 23: 564-8
23. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71
24. Llovet JM, Real Ml, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734-9
25. Yao FY, Kerlan RK, Hirose R, et al. Excellent outcomes following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48(3): 819-827
26. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4: 424-432
27. Lesurtel M, Mullhaupt B, Pestalozzi ВС, et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6(11): 2644-50
28. Maddala YK, Stadheim L, Andrews JC, et al. Dropout rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10:449-55
29. Richard HM 3rd, Silberzweig JE, Mitty HA, et al. Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellulat carcinoma. Radiology 2000; 214: 775-9
30. Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007; 17: 1025-34
31. Martinelli DJ, Wadler S, Bakal CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994; 74: 1706-12
32. Lang EK, Brown CL. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993; 189: 417-22
33. Taniai N, Onda M, Tajiri T, et al. Good embolization response for colorectal liver metastases with hypervascularity Hepatogastroenterology 2002; 49: 1531-4
34. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776-83
35. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511
36. Ruszniewski P, OToole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 2004; 80 (Suppl 1): 74-8
37. Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma:natural history, current management, and emerging tools. Biologies 2012; 6: 207-219
38. Chan АО, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2001; 94: 1747-52
39. Wigmore SJ, Redhead DN, Thomson BN, et al. Postchemoembolization syndrome: tumour necrosis or hepatocyte injury? Br J Cancer 2003; 89: 1423-7.